Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

Volker Heinemann, MD, PhD
Published: Monday, Oct 24, 2016



Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer (CRC).

The general goal, says Heinemann, is to find a surrogate parameter that can be measured early on and which relates a patient's response to overall survival. Through the use of depth of response, oncologists can, in fact, find early tumor shrinkage in patients with CRC, and relate that to prolonged survival.

Depth of response goes one step beyond the RECIST criteria, according to Heinemann. RECIST differentiates responses with categories like partial and complete responses, whereas depth of response is a continuous parameter. Therefore, says Heinemann, depth of response allows oncologists to more precisely demonstrate how effective a treatment was for a particular patient.


Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer (CRC).

The general goal, says Heinemann, is to find a surrogate parameter that can be measured early on and which relates a patient's response to overall survival. Through the use of depth of response, oncologists can, in fact, find early tumor shrinkage in patients with CRC, and relate that to prolonged survival.

Depth of response goes one step beyond the RECIST criteria, according to Heinemann. RECIST differentiates responses with categories like partial and complete responses, whereas depth of response is a continuous parameter. Therefore, says Heinemann, depth of response allows oncologists to more precisely demonstrate how effective a treatment was for a particular patient.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x